Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	388	174	88	28	29	38
Market Cap Growth	107.85%	97.16%	219.36%	-4.32%	-24.65%	-66.14%
Enterprise Value	397	209	118	44	34	23
Last Close Price	19.38	8.95	4.95	1.55	1.62	2.15
PE Ratio	17.43	11.72	-	-	-	-
Forward PE	-	10.63	-	7.84	-	-
PS Ratio	6.94	3.61	10.48	4.59	4.84	6.74
PB Ratio	262.52	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	262.68	127.32	-	-	8.98	2.06
EV/Sales Ratio	7.09	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	12.00	8.52	-	-	-	-
EV/EBIT Ratio	12.06	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Net Debt / Equity Ratio	5.92	27.88	-1.20	-1.63	2.73	-0.28
Net Debt / EBITDA Ratio	0.27	1.55	-3.12	-1.72	-0.69	0.27
Net Debt / FCF Ratio	0.38	-2.31	-3.53	-2.06	-0.74	0.31
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	6.10%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	5.91%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.